Original ArticleThe patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice
-
Add time:09/04/2019 Source:sciencedirect.com
BackgroundTrials have demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective as an adjunct to statin therapy, but access and cost issues have limited their use in community practice.
We also recommend Trading Suppliers and Manufacturers of SUBTILISINS (cas 1395-21-7). Pls Click Website Link as below: cas 1395-21-7 suppliers
Prev:Insight into subtilisin E-S7 cleavage pattern based on crystal structure and hydrolysates peptide analysis
Next:Design of antimicrobial polycaprolactam nanocomposite by immobilizing subtilisin conjugated Au/Ag core-shell nanoparticles for biomedical applications) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Identification of a new subtilisin-like protease NbSLP2 interacting with cytoskeletal protein septin in Microsporidia Nosema bombycis09/09/2019
- Enhancing the catalytic efficiency of subtilisin for transesterification by dual bioimprinting09/08/2019
- AJM onlineReviewProprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview09/07/2019
- A novel detergent additive: Organic solvent- and thermo-alkaline-stable recombinant subtilisin09/06/2019
- Design of antimicrobial polycaprolactam nanocomposite by immobilizing subtilisin conjugated Au/Ag core-shell nanoparticles for biomedical applications09/05/2019
- Insight into subtilisin E-S7 cleavage pattern based on crystal structure and hydrolysates peptide analysis09/03/2019
- NMR structure of CmPI-II, a non-classical Kazal protease inhibitor: Understanding its conformational dynamics and subtilisin A inhibition09/02/2019
- Heterologous expression and characterization of a novel subtilisin-like protease from a thermophilic Thermus thermophilus HB809/01/2019
